AKT1 and melanoma: To validate our hypothesis that RA could down-regulate ADAM17 expression and inhibit EGFR/AKT signaling to inhibit the progression of melanoma, ADAM17 was overexpressed in A375 cells and results in Figure 4a and Figure 4b demonstrated the significant elevation in mRNA and protein expression of ADAM17.